Patents Assigned to Immugen Pharmaceuticals Inc.
  • Patent number: 9173867
    Abstract: This invention discloses cannabinoid derivatives and pharmaceutical uses thereof.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: November 3, 2015
    Assignee: IMMUGEN PHARMACEUTICALS, INC.
    Inventor: Craig Travis
  • Publication number: 20040242870
    Abstract: The invention provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. In accordance with the invention, at least one cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus.
    Type: Application
    Filed: April 5, 2004
    Publication date: December 2, 2004
    Applicant: Immugen Pharmaceuticals, Inc.
    Inventor: Craig R. Travis
  • Publication number: 20040138315
    Abstract: The invention provides a method for attenuating the aggregation and/or activation of blood platelets within a blood product. In accordance with this method, a cannabinoid or resorcinolic compound is introduced into the blood product under conditions sufficient to inhibit the aggregation and/or activation of blood platelets within the blood product. The invention also pertains to the use of a cannabinoid or resorcinolic compound to prepare a composition suitable for inhibiting the activation and/or aggregation of blood platelets and to such compositions. The invention also pertains to a method of selectively inhibiting COX-1 and thromboxane synthase within a cell or blood platelet.
    Type: Application
    Filed: December 16, 2003
    Publication date: July 15, 2004
    Applicant: Immugen Pharmaceuticals, Inc.
    Inventor: Craig R. Travis
  • Publication number: 20030232101
    Abstract: In one aspect, the invention provides a method for preventing the transmission of HIV from one individual to another. In accordance with the method, a pharmacologically-acceptable composition including at least one resorcinol derivative compound and/or cannabinoid (e.g., cannabinol derivatives, &Dgr;8-THC derivatives, cannabichromene derivatives, cannabidiol derivatives, cannabigerol derivatives) (including combinations thereof) is administered topically to a first individual harboring HIV, or to a second individual at risk of infection with HIV, proximate in time with contact between the first individual and the second individual. The invention also provides topical formulations of at least one resorcinol and/or cannabinoid and water insoluble polymers as hydrogels.
    Type: Application
    Filed: March 18, 2003
    Publication date: December 18, 2003
    Applicant: Immugen Pharmaceuticals, Inc.
    Inventor: Craig R. Travis
  • Publication number: 20030171372
    Abstract: The invention provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. In accordance with the invention, at least one cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus.
    Type: Application
    Filed: January 16, 2003
    Publication date: September 11, 2003
    Applicant: Immugen Pharmaceuticals, Inc.
    Inventor: Craig R. Travis
  • Patent number: 6566560
    Abstract: The invention provides a resorcinol derivative and a method of using the resorcinol derivative to attenuate the growth of a neoplasm.
    Type: Grant
    Filed: August 13, 2001
    Date of Patent: May 20, 2003
    Assignee: Immugen Pharmaceuticals, Inc.
    Inventor: Craig R. Travis
  • Patent number: 6541510
    Abstract: The invention provides a method, compounds, and compositions for inhibiting the replication or proliferation of a virus. In accordance with the invention, at least one cannabichromene derivative is exposed to the virus, a host cell, or an infected cell under conditions sufficient to inhibit the replication or proliferation of the virus.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: April 1, 2003
    Assignee: Immugen Pharmaceuticals, Inc.
    Inventor: Craig R. Travis
  • Patent number: 6274635
    Abstract: The present invention provides a method, compounds, and compositions for treating a disease associated with immune dysfunction. In accordance with the method, a pharmacologically-acceptable composition including at least one compound selected from the group of compounds consisting of 5-alkyl-resorcinol derivatives, cannabinol derivatives, cannabidiol derivatives, cannabigerol derivatives, and combinations thereof is administered to a patient under conditions sufficient to attenuate the dysfunction within the immune system. The invention also provides an antiviral cannabinol derivative that can be used in the inventive method. The invention also provides an alkylated resorcinol derivative and a method of using the alkylated resorcinol derivative to attenuate the growth of a neoplasm. The method and compound are useful for treating diseases of the immune system, such as HIV disease and neoplastic disorders.
    Type: Grant
    Filed: March 22, 2000
    Date of Patent: August 14, 2001
    Assignee: Immugen Pharmaceuticals Inc.
    Inventor: Craig A. Travis